Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.990
+0.110 (5.85%)
Mar 9, 2026, 4:00 PM EDT - Market closed

Cardiff Oncology Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-45.85-45.43-41.44-38.7-28.29
Upgrade
Depreciation & Amortization
0.90.940.40.240.45
Upgrade
Loss (Gain) From Sale of Assets
---00
Upgrade
Loss (Gain) From Sale of Investments
-0.85-0.6-0.920.631.61
Upgrade
Stock-Based Compensation
5.694.764.514.263.23
Upgrade
Other Operating Activities
---0.141.75
Upgrade
Change in Accounts Receivable
0.59-0.480.48-0.24-0.22
Upgrade
Change in Accounts Payable
2.22.992.831.350.72
Upgrade
Change in Other Net Operating Assets
-0.610.133.25-1.49-2.29
Upgrade
Operating Cash Flow
-37.92-37.69-30.89-33.82-23.04
Upgrade
Capital Expenditures
-0.04-0.08-0.58-1.01-0.21
Upgrade
Investment in Securities
1.3913.8136.7839.04-131.24
Upgrade
Other Investing Activities
---0.11-
Upgrade
Investing Cash Flow
1.3413.7336.238.15-131.45
Upgrade
Issuance of Common Stock
2.5853.78-0.0836.26
Upgrade
Other Financing Activities
-----0.81
Upgrade
Financing Cash Flow
2.5853.78-0.0835.45
Upgrade
Net Cash Flow
-3429.825.314.4-119.04
Upgrade
Free Cash Flow
-37.97-37.77-31.47-34.83-23.25
Upgrade
Free Cash Flow Margin
-6402.53%-5530.45%-6448.57%-9022.28%-6474.93%
Upgrade
Free Cash Flow Per Share
-0.57-0.79-0.70-0.80-0.60
Upgrade
Cash Income Tax Paid
00-00
Upgrade
Levered Free Cash Flow
-19.62-22.53-18.01-21.04-16.74
Upgrade
Unlevered Free Cash Flow
-19.62-22.53-18.01-21.04-16.74
Upgrade
Change in Working Capital
2.182.636.57-0.38-1.79
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.